The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, including blood and bone marrow cancers, leukemia, and myeloma.
July 31st 2025
Sanofi's SAR446523 receives orphan drug designation for relapsed refractory multiple myeloma, enhancing treatment options and patient outcomes.
FDA Grants Accelerated Approval to Elranatamab-bcmm for Relapsed or Refractory Multiple Myeloma
August 14th 2023Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Read More
Simulation Demonstrates Potential Effectiveness of Model-Informed Precision Dosing for Heparin
August 14th 2023The growing awareness in health care of the challenges associated with proper dosing of anticoagulants such as heparin has inspired the emerging field of anticoagulation stewardship.
Read More
Novel Combination Targeting BCR::ABL1 in Ph+ ALL With TKIs, STAMP-Inhibitor Is Very Well Tolerated
Pharmacists will play a significant role in TKI adherence rates among patients.
Read More
Case Study: New Treatment Options for Patients With Chronic Lymphocytic Leukemia
August 2nd 2023With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.
Read More
Axatilimab Produces Significant Response in Patients with Fatal Post-Transplant Complication
July 25th 2023Co-developers Incyte and Syndax will submit a biologics license application to the FDA at the end of 2023 based on the results of a phase 2 trial among adult and pediatric patients with chronic graft-versus-host disease.
Read More
As Chemotherapy Drug Shortage Continues, Unimaginable Decisions and Lacking Accountability Reign
July 24th 2023Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.
Read More
Expert Panel Discusses Advocacy, Education for Patients With Myeloproliferative Neoplasms
July 14th 2023Despite a slew of barriers with patient management, pharmacists have the training and resources to advocate for better patient care and help patients with hematologic myeloproliferative neoplasms advocate for themselves.
Read More
Luspatercept-aamt Shows Efficacy Treating Anemia Due to Myelodysplastic Syndromes
June 19th 2023Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.
Read More